MedTrace Logo

Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer

NCT00004008 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have ovarian epithelial cancer that has not responded to previous chemotherapy.

Conditions

Interventions

DRUG

bryostatin 1

Sponsors & Collaborators

  • University of Glasgow

    lead OTHER

Principal Investigators

  • Gordon Jayson, MD · The Christie NHS Foundation Trust

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31
Completion
2003-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004008 on ClinicalTrials.gov